9601 Jeronimo Road Irvine, CA, 92618 United StatesBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

238 Changjiang Road Shijiazhuang, 050031 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Building 1, Lane 917, Halei Road Zhangjiang High Tech Park Pudong District, Shanghai, 201203 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Building 8, 249 Faladi Road China (Shanghai) Pilot Free Trade Zone Pudong District, Shanghai, 201203 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

11011 Torreyana Rd San Diego, CA 92121 United StatesBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Building E, No. 29 Life Science Park Road Changping District, Beijing, 102206 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Building 8, 388 Jialilue Road Zhangjiang High Tech Park Pudong District, Shanghai, 201203 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

238 Changjiang Road Shijiazhuang, Hebei, 050031 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Room 501, Complex Building, No.30 Feihe Road Mohekou Industrial Park, Huaishang District, Bengbu, Anhui, 233018 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Floor 3, 665 Zhangjiang Road Pilot Free Trade Zone Pudong District, Shanghai, 200131 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

7/F, 107 Ren Ai Road Sec, 4, Da An District , Taipei City, 10689 TaiwanBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

No. 1699, Huishan Avenue Huishan Economic Development Zone Wuxi, Jiangsu, 214174 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

No. 233 North Fu Te Road Waigaoqiao Free Trade Zone Shanghai, Shanghai, 200131 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

11011 Torreyana Rd San Diego, CA, 92121 United StatesBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

2804 Gateway Oaks, Dr. #100, Sacramento, CA, 95833 United StatesBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Building G5, Jintuo Road Mohekou Industrial Park, Huaishang District, Bengbu, Anhui, 10689 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.

Changping District No. 29 Life Science Park Road Beijing, Beijing, 102206 ChinaBioDuro: Global CRDMO, Rooted in Science BioDuro is a US-headquartered contract research, development and manufacturing organization with a 30-year track record, founded in 1996 in Irvine, California and backed by Advent and Bridgewest. More than 2,000 scientists, half holding advanced degrees, serve over 1,500 customers in more than 30 countries, including 14 of the top 20 global pharmaceutical companies. We have supported over 500 IND filings across FDA and NMPA, delivering on-time, cost-competitive programs with industry-leading timelines. Integrated discovery through IND, engineered for speed: We run discovery chemistry, biology and DMPK as one program at a single site, with a dedicated project manager and every functional leader in the weekly client meeting. That structure removes the handoffs, requalification and data-transfer delays that slow multi-vendor programs. - Hit to preclinical candidate (PCC) in 16 months, across 400+ compounds synthesized and tested - 11 months to IND, running API, drug product and filing workstreams in parallel under one quality system with a single point of contact - DMPK in vitro assays and in vivo studies returned in approximately 5 days - IND-ready formulations in 8 to 12 weeks through our Solution Engine platform - Condition screening for difficult chemistry in under one day, with 99% on-time delivery Modality depth where programs are hardest: Small molecules; peptides, macrocycles and oral peptides; antibody-drug conjugates and XDCs including PDCs and RDCs; targeted protein degradation spanning PROTACs, molecular glues and RIPTACs; oligonucleotides and nucleosides. High-potency payloads are synthesized in OEB 4/5 compliant laboratories, including a dedicated OEB-5 high potency synthesis lab. Degrader biology covers cell permeability, binary target engagement, ternary complex formation, ubiquitination and endogenous target degradation. Dedicated platforms support GLP-1 research and diet-induced obesogenic MASH models. Our Peptide business unit delivers 10,000+ molecules annually across all peptide types and conjugates, integrating AI-enabled screening, DNA-encoded libraries, and SPPS and LPPS synthesis. Therapeutic area expertise: oncology and immuno-oncology, immunology and inflammation, metabolic and cardiovascular disease including obesity and MASH, respiratory, central nervous system, and rare disease. Resourced as an extension of your team: Fee-for-service for defined work. Dedicated FTE chemistry, biology and DMPK teams for sustained programs. Fully integrated multi-function programs where BioDuro drives design. Scale flexes as the program grows: 1,300+ chemists across four sites delivering 72,000+ molecules annually, 140+ biologists supported by 1,000+ in vitro assays and 600+ in vivo models, 160+ DMPK scientists across two AAALAC and OLAW accredited vivarium facilities, and 280+ process R&D scientists. Development and CMC supply: Process R&D, scale-up and API manufacturing with more than 480,000 L total reactor volume and kilo-scale synthesis at seven days per step. Drug product from preformulation through clinical and registration batch manufacturing up to Phase III, with bioavailability enhancement by spray drying, hot melt extrusion, particle engineering and lipid formulation. GMP API capacity in Taiwan provides an ex-China manufacturing option with an FDA inspection history spanning 2014 through 2024. Why partners stay: A right-sized organization with a flat structure and western-trained scientific leadership, delivering cost-competitive science, rapid decision-making, >99% on-time delivery, and high-touch engagement. ISO 27001 certified for information security and ISO 14001 for environmental management, with EcoVadis Gold ratings placing two sites in the global top 3% and top 5%. Sole champion in Small Molecule Dosage Form Global at the 2025 CDMO Leadership Awards, where 210 CDMOs are rated purely by their customers, and recipient of Scientist.com Supplier Performance Recognition. Together, these accelerate timelines, reduce program cost, and increase the probability of clinical success.